jumps

spawns Amylyx Pharmaceuticals (NASDAQ:AMLX) traded sharply higher on Wednesday after the drug developer announced the acquisition of avexitide, a GLP-1 receptor antagonist developed by Eiger BioPharmaceuticals (OTC:EIGRQ). The transaction was completed on July 9 after Amylyx (AMLX) emerged as the winning bidder in an auction held to sell Avexitide underContinue Reading

Sean Anthony Eddy Insurance products distributor in China — Fanhua (NASDAQ:FANH) board of directors authorized the expansion share repurchase program by an additional $20M, bringing total authorized repurchase to $40M. As of June 30, 2024, ~726,616 ADS had been repurchased at an aggregate purchase price of ~$5.4M since the inceptionContinue Reading